# Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

> **NCT04126733** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 70 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)
- **BIOLOGICAL:** Nivolumab (Opdivo)

## Key facts

- **NCT ID:** NCT04126733
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-14
- **Primary completion:** 2020-11-11
- **Final completion:** 2022-03-28
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126733, "Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04126733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*